CALT - Calliditas Therapeutics GAAP EPS of -SEK 3.95 revenue of SEK 49.7M
Calliditas Therapeutics press release (NASDAQ:CALT): Q1 GAAP EPS of -SEK 3.95. Revenue of SEK 49.7M. Cash amounted to SEK 825.4M and SEK 867.3M as of March 31, 2022 and 2021, respectively.
For further details see:
Calliditas Therapeutics GAAP EPS of -SEK 3.95, revenue of SEK 49.7M